(Q54499836)
Statements
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. (English)
Saoirse Dolly
Maria Martinez-Garcia
Joan Albanell
Rastilav Bahleda
Federico Rojo
Emilie Routier
Ernesto Guarin
Zhi-Xin Xu
Ruediger Rueger
Jean J L Tessier
Eliezer Shochat
Steve Blotner
Valerie Meresse Naegelen
Jean-Charles Soria
3 July 2012
4806-4819